IDEXX Laboratories, Inc.
IDXXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframePart of the healthcare sector, IDEXX Laboratories, Inc. (IDXX) is listed under Diagnostics & Research. At a $43.45B market cap, IDEXX Laboratories, Inc. ranks as a large-cap company within healthcare. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Market Cap
$43.45B
Beta
1.57
P/E (TTM)
40.47
P/E (Fwd)
33.35
EPS (TTM)
$13.61
EPS (Fwd)
$16.52
ROE
72.9%
ROA
26.5%
Cash
$200.5M
Total Debt
$1.11B
Free CF
$786.8M
52W Change
5.0%
Annual Financials
Cash vs Debt
The company holds $200.5M in cash, though total debt stands at $1.11B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $786.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 72.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 26.5% further supports the picture of efficient asset utilization. Revenue has grown from $3.37B (2022) to $4.30B (2025), reflecting a 28% increase over the period.
IDEXX Laboratories, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence IDEXX Laboratories, Inc.'s trajectory.